Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001104659-25-014361
Filing Date
2025-02-14
Accepted
2025-02-14 18:24:06
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 17121
  Complete submission text file 0001104659-25-014361.txt   19100
Mailing Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010 646-844-0337
Protara Therapeutics, Inc. (Subject) CIK: 0001359931 (see all company filings)

EIN.: 204580525 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-88372 | Film No.: 25631662
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address SOUTHEAST FINANCIAL CENTER 200 S. BISCAYNE BLVD., SUITE 3300 MIAMI FL 33131
Business Address SOUTHEAST FINANCIAL CENTER 200 S. BISCAYNE BLVD., SUITE 3300 MIAMI FL 33131 305-929-6851
CITADEL ADVISORS LLC (Filed by) CIK: 0001423053 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A